Lb Pharmaceuticals (LBRX) Income towards Parent Company (2024 - 2026)

Lb Pharmaceuticals' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 259.1% year-over-year to -$19.1 million in Q1 2026; TTM through Mar 2026 was -$39.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25.2 million, up 60.06% from the prior year.
• Income towards Parent Company slipped to -$19.1 million in Q1 2026 per LBRX's latest filing, from -$11.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$3.6 million in Q3 2025 and bottomed at -$19.1 million in Q1 2026.
• The 3-year median for Income towards Parent Company is -$8.4 million (2025), against an average of -$9.8 million.
• Across the five-year window, Income towards Parent Company soared 74.92% in 2025 and slumped 259.1% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$5.1 million in 2024, then slumped by 126.23% to -$11.5 million in 2025, then sank by 66.09% to -$19.1 million in 2026.
• Per Business Quant, the three latest LBRX Income towards Parent Company figures stand at -$19.1 million (Q1 2026), -$11.5 million (Q4 2025), and -$3.6 million (Q3 2025).